Skip to main content

Johnson & Johnson stock price and financials

  • JNJ · NYSE
  • Healthcare
  • Pharmaceuticals
  • S&P 500
$285.75+0.79%Close 13 Nov 2026
Market value
$686.1B
P/E
42.63
EV / EBITDA
21.79
Dividend yield
1.9%
Beta · 1 year
−0.08
Return · 1 year
+47.0%
52-week range$193.45 — $288.11

Share price close 16 Nov 2026

+12.3%1 monthHigh $285.75Low $253.79
$250$260$270$280$290Q3 FY2026 report filed 21 Oct 202623 Oct29 Oct4 Nov10 Nov16 Nov
+25.5%6 monthsHigh $285.75Low $222.89
$220$240$260$280$300Q2 FY2026 report filed 23 Jul 2026Q3 FY2026 report filed 21 Oct 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+37.4%year to dateHigh $285.75Low $204.31
$200$225$250$275$300Q4 FY2025 report filed 11 Feb 2026Q1 FY2026 report filed 22 Apr 2026Q2 FY2026 report filed 23 Jul 2026Q3 FY2026 report filed 21 Oct 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+45.2%1 yearHigh $285.75Low $199.58
$175$200$225$250$275$300Q4 FY2025 report filed 11 Feb 2026Q1 FY2026 report filed 22 Apr 2026Q2 FY2026 report filed 23 Jul 2026Q3 FY2026 report filed 21 Oct 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+91.1%3 yearsHigh $285.75Low $142.06
$100$150$200$250$300Q4 FY2023 report filed 16 Feb 2024Q1 FY2024 report filed 1 May 2024Q2 FY2024 report filed 25 Jul 2024Q3 FY2024 report filed 23 Oct 2024Q4 FY2024 report filed 13 Feb 2025Q1 FY2025 report filed 23 Apr 2025Q2 FY2025 report filed 24 Jul 2025Q3 FY2025 report filed 22 Oct 2025Q4 FY2025 report filed 11 Feb 2026Q1 FY2026 report filed 22 Apr 2026Q2 FY2026 report filed 23 Jul 2026Q3 FY2026 report filed 21 Oct 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+147%10 yearsHigh $285.75Low $111.96
$100$150$200$250$300Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Johnson & Johnson reported revenue of $94.2 billion for fiscal year 2025 (the twelve months to 28 Dec 2025), up 6.0% from fiscal 2024. Net income was $26.8 billion and diluted earnings per share $11.03.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 27 Sep 2026), revenue was $25.4 billion, up 5.9% from a year earlier.

Figures from Johnson & Johnson's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 21 Oct 2026.

Against Health Care

Growth
Bottom quarter
Revenue +2.7% a year over five years · 32nd of 37
Profitability
Upper half
Return on invested capital 13.9%, five-year average · 12th of 38
Balance sheet
Upper half
Net debt 0.8× EBITDA · 13th of 38
Valuation
Above the median
P/E 42.6 · 25th of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$94.19B+6.0%
Net income
$26.80B+90.6%
Diluted EPS
$11.03+90.5%
Gross margin
67.9%−1.2 pts
Free cash flow
$19.70B−0.7%
Net debt
$31.23B+107%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$20B$40B$60B$80B$100BRevenue, FY16: $71.89BNet income, FY16: $16.54BFY16Revenue, FY17: $76.45BNet income, FY17: $1.3BFY17Revenue, FY18: $81.58BNet income, FY18: $15.3BFY18Revenue, FY19: $82.06BNet income, FY19: $15.12BFY19Revenue, FY20: $82.58BNet income, FY20: $14.71BFY20Revenue, FY21: $78.74BNet income, FY21: $20.88BFY21Revenue, FY22: $79.99BNet income, FY22: $17.94BFY22Revenue, FY23: $85.16BNet income, FY23: $35.15BFY23Revenue, FY24: $88.82BNet income, FY24: $14.07BFY24Revenue, FY25: $94.19BNet income, FY25: $26.8BFY25

Latest quarter · Q3 FY2026 to 27 Sep 2026, filed 21 Oct 2026 · Full results →

Revenue
$25.40B+5.9% on a year
Gross margin
68.1%−1.4 pts on a year
Operating income
$5.84B−16.9% on a year
Net income
$210.0M−95.9% on a year
Diluted EPS
$0.09−95.8% on a year
Free cash flow
$6.36B−20.6% on a year

Comparable companies All of Health Care →

Johnson & Johnson beside the other S&P 500 members in Pharmaceuticals, by market value.

Johnson & Johnson and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Johnson & JohnsonJNJ$686.1B+0.8%+47.0%+7.8%16.2%42.6
Eli LillyLLY$1.37T+1.1%+41.8%+45.5%31.9%49.6
Bristol Myers SquibbBMY$128.5B+1.8%+29.2%+4.2%18.5%13.9
Merck & Co.MRK—+0.6%+61.6%———
PfizerPFE—+0.2%+11.7%———
ViatrisVTRS—+0.7%+89.1%———
ZoetisZTS—+1.0%−30.9%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%25%50%75%67.9%28.5%26.8%FY16FY19FY22FY25

Johnson & Johnson revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Johnson & Johnson revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Innovative Medicine$51.68B$52.56B+1.7%$54.76B+4.2%$56.96B+4.0%$60.40B+6.0%
MEDTECH$27.06B$27.43B+1.4%$30.40B+10.8%$31.86B+4.8%$33.79B+6.1%
Total revenue$78.74B$79.99B$85.16B$88.82B$94.19B

By region

Johnson & Johnson revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$40.64B$41.98B+3.3%$46.44B+10.6%$50.30B+8.3%$53.75B+6.9%
Europe$20.59B$20.66B+0.3%$20.41B−1.2%$20.21B−1.0%$21.54B+6.5%
Asia-Pacific, Africa$13.58B$13.24B−2.5%$13.76B+3.9%$13.59B−1.2%$14.03B+3.2%
Western Hemisphere, excluding U.S.$3.93B$4.11B+4.6%$4.55B+10.7%$4.71B+3.6%$4.88B+3.4%
Total revenue$78.74B$79.99B$85.16B$88.82B$94.19B

Financial statements

Fiscal years, the latest ending 28 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Johnson & Johnson income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$71.89B$76.45B$81.58B$82.06B$82.58B$78.74B$79.99B$85.16B$88.82B$94.19B
Revenue growth+2.6%+6.3%+6.7%+0.6%+0.6%−4.7%+1.6%+6.5%+4.3%+6.0%
Gross profit$50.10B$51.01B$54.49B$54.50B$54.16B$55.34B$55.39B$58.61B$61.35B$63.94B
Operating income$20.37B$18.18B$19.80B$19.81B$19.49B$19.83B$19.95B$21.21B$20.80B$25.29B
Net income$16.54B$1.30B$15.30B$15.12B$14.71B$20.88B$17.94B$35.15B$14.07B$26.80B
Diluted EPS$5.93$0.47$5.61$5.63$5.51$7.81$6.73$13.72$5.79$11.03
Gross margin69.7%66.7%66.8%66.4%65.6%70.3%69.3%68.8%69.1%67.9%
Operating margin28.3%23.8%24.3%24.1%23.6%25.2%24.9%24.9%23.4%26.8%
Net margin23.0%1.7%18.8%18.4%17.8%26.5%22.4%41.3%15.8%28.5%

Cash flow

Johnson & Johnson cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$18.77B$21.06B$22.20B$23.42B$23.54B$23.41B$21.19B$22.79B$24.27B$24.53B
Capital expenditure$3.23B$3.28B$3.67B$3.50B$3.35B$3.65B$4.01B$4.54B$4.42B$4.83B
Free cash flow$15.54B$17.78B$18.53B$19.92B$20.19B$19.76B$17.18B$18.25B$19.84B$19.70B

Balance sheet and shares

Johnson & Johnson balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$18.97B$17.82B$18.11B$17.30B$13.98B$14.49B$12.89B$21.86B$24.11B$19.71B
Total debt$28.83B$36.08B$33.08B$28.69B$38.16B$36.88B$42.49B$31.90B$39.58B$51.33B
Shareholders' equity$70.42B$60.16B$59.75B$59.47B$63.28B$74.02B$76.80B$68.77B$71.49B$81.54B
Diluted shares2.8B2.7B2.7B2.7B2.7B2.7B2.7B2.6B2.4B2.4B
Dividends per share$3.15$3.32$3.54$3.75$3.98$4.19$4.45$4.70$4.91$5.14

Quarterly figures

The last eight fiscal quarters, the latest ending 27 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Johnson & Johnson quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$22.52B$21.89B$23.74B$23.99B$24.56B$24.06B$25.31B$25.40B
Revenue, year on year+5.3%+2.4%+5.8%+6.8%+9.1%+9.9%+6.6%+5.9%
Gross margin68.3%66.4%67.9%69.6%67.6%66.3%68.2%68.1%
Operating income$3.58B$6.18B$6.65B$7.03B$5.43B$6.33B$7.14B$5.84B
Net income$3.43B$11.00B$5.54B$5.15B$5.12B$5.24B$5.53B$210.0M
Diluted EPS$1.41$4.54$2.29$2.12$2.09$2.14$2.27$0.09
Free cash flow$5.37B$3.38B$2.83B$8.01B$5.47B$1.47B$7.29B$6.36B

Operating KPIs

The operating figures Johnson & Johnson reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Johnson & Johnson operating KPIs
KPILatestPeriodChange on a yearRecent periods
MedTech worldwide operational sales (change on a year)2.5%quarter to 27 Sep 2026down 3.1 points
Oncology revenue$7.6Bquarter to 27 Sep 2026up 16.4%
Immunology revenue$4.2Bquarter to 27 Sep 2026up 1.3%
Neuroscience revenue$2.4Bquarter to 27 Sep 2026up 17.3%
Cardiovascular revenue$2.3Bquarter to 27 Sep 2026up 4.2%
Pulmonary Hypertension revenue$897.0Mquarter to 27 Sep 2026down 19.6%
Cardiovascular/Metabolism/Other revenue$849.0Mquarter to 27 Sep 2026down 5.6%
Infectious Diseases revenue$813.0Mquarter to 27 Sep 2026down 1.9%
Shockwave revenue$325.0Mquarter to 27 Sep 2026up 16.9%
Innovative Medicine revenue$16.8Bquarter to 27 Sep 2026up 7.7%
MEDTECH revenue$8.6Bquarter to 27 Sep 2026up 2.5%
United States revenue$15.0Bquarter to 27 Sep 2026up 9.1%
Non-US revenue$10.4Bquarter to 27 Sep 2026up 1.5%
Europe revenue$5.4Bquarter to 27 Sep 2026down 0.6%
Asia-Pacific, Africa revenue$3.7Bquarter to 27 Sep 2026up 1.0%
Western Hemisphere, excluding U.S. revenue$1.4Bquarter to 27 Sep 2026up 12.5%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Johnson & Johnson's revenue in fiscal 2025?

$94.2 billion for fiscal year 2025 (the twelve months to 28 Dec 2025), as reported in its annual report.

What was Johnson & Johnson's net income in fiscal 2025?

$26.8 billion for fiscal year 2025 (the twelve months to 28 Dec 2025).

What were Johnson & Johnson's diluted earnings per share in fiscal 2025?

$11.03 for fiscal year 2025 (the twelve months to 28 Dec 2025).

What is Johnson & Johnson's gross margin?

67.9% for fiscal year 2025 (the twelve months to 28 Dec 2025): gross profit divided by revenue.

What is Johnson & Johnson's operating margin?

26.8% for fiscal year 2025 (the twelve months to 28 Dec 2025): operating income divided by revenue.

How much free cash flow did Johnson & Johnson generate in fiscal 2025?

$19.7 billion for fiscal year 2025 (the twelve months to 28 Dec 2025): operating cash flow less capital expenditure.

Where does Johnson & Johnson's revenue come from?

In fiscal 2025, by segment: Innovative Medicine $60.40B (64%), MEDTECH $33.79B (36%), out of $94.19B in all, as stated in its annual report.

In the terminal

Twenty years of Johnson & Johnson's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans